Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06058793
Other study ID # 1403-0019
Secondary ID 2023-504522-19-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 12, 2023
Est. completion date November 30, 2025

Study information

Verified date May 2024
Source Boehringer Ingelheim
Contact Boehringer Ingelheim
Phone 1-800-243-0127
Email clintriage.rdg@boehringer-ingelheim.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check participants' health and take note of any unwanted effects. The doctors also regularly check tumour size.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date November 30, 2025
Est. primary completion date November 24, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to any study-specific procedures, sampling, or analyses 2. Male or female patients =18 years old at the time of signature of the ICF 3. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use two medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at screening, during study participation, and until 6 months and 12 days after last dose for women and 102 days after last dose for men. A list of contraception methods meeting these criteria is provided in the patient information 4. Histologically documented locally advanced or metastatic, unresectable (i.e. surgery morbidity would outweigh potential benefits), progressive or recurrent Dedifferentiated liposarcoma (DDLPS), meeting the criteria for an open study cohort: - Cohort A: patient has not received prior systemic therapy for DDLPS in any setting (including adjuvant, neoadjuvant, maintenance, palliative) - Cohort B: patient has received any prior systemic therapy for DDLPS in any setting (including adjuvant, neoadjuvant, maintenance, palliative) 5. Written pathology report indicating the diagnosis of DDLPS with positive MDM2 immunohistochemistry or MDM2 amplification as demonstrated by fluorescence in situ hybridisation (FISH) or next-generation sequencing (NGS) 6. Presence of at least 1 measurable target lesion according to RECIST version 1.1. In patients who only have 1 target lesion, the baseline imaging must be performed at least 2 weeks after any biopsy of the target lesion 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. Life expectancy =3 months at the start of treatment in the opinion of the investigator Further inclusion criteria apply. Exclusion Criteria: 1. Known mutation in the TP53 gene (screening for TP53 status is not required) 2. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of study treatment or planned within 6 months after screening 3. Previous administration of brigimadlin or any other MDM2-p53 or MDM4 regulator of p53 (MDM4/MDMX)-p53 antagonist 4. Previous treatment in study 1403-0008 (Brightline-1) 5. Having to receive, or intending to receive, restricted medications or any drug considered likely to interfere with the safe conduct of the study 6. Receiving treatment for brain metastases or leptomeningeal disease (LMD) which may interfere with safety and/or endpoint assessment 7. Unable to swallow the study treatment 8. Previous or concomitant malignancies other than the one treated in this study within the previous 2 years, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ, or other malignancy that is considered cured by local treatment Further exclusion criteria apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brigimadlin
Brigimadlin

Locations

Country Name City State
Argentina Sanatorio Finochietto Caba
Australia Peter MacCallum Cancer Centre Melbourne Victoria
Australia Sir Charles Gairdner Hospital Nedlands Western Australia
Australia Prince of Wales Hospital Randwick New South Wales
Australia Princess Alexandra Hospital Woolloongabba Queensland
Brazil Hospital do Cancer de Londrina Londrina
Brazil CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia Santo André
Brazil Hospital Sao Domingos Sao Luis
Brazil H.S.J. Beneficência Portuguesa - São Paulo Sao Paulo
Canada Princess Margaret Cancer Centre Toronto Ontario
Japan Aichi Cancer Center Hospital Aichi, Nagoya
Japan Nagoya University Hospital Aichi, Nagoya
Japan National Cancer Center Hospital East Chiba, Kashiwa
Japan Kyushu University Hospital Fukuoka, Fukuoka
Japan National Hospital Organization Kyushu Cancer Center Fukuoka, Fukuoka
Japan Tohoku University Hospital Miyagi, Sendai
Japan Okayama University Hospital Okayama, Okayama
Japan Osaka International Cancer Institute Osaka, Osaka
Japan Hokkaido Cancer Center Sapporo, Hokkaido
Japan Japanese Foundation for Cancer Research Tokyo, Koto-ku
United Kingdom Addenbrooke's Hospital Cambridge
United Kingdom Beatson West of Scotland Cancer Centre Glasgow
United Kingdom The Royal Marsden Hospital, Chelsea London
United Kingdom The Christie Hospital Manchester
United States University Cancer and Blood Center Athens Georgia
United States Precision NextGen Oncology Beverly Hills California
United States University of Alabama at Birmingham Birmingham Alabama
United States Northwestern University Chicago Illinois
United States Duke University Medical Center Durham North Carolina
United States Virginia Cancer Specialists, PC Fairfax Virginia
United States West Cancer Center & Research Institute Germantown Tennessee
United States John Theurer Cancer Center Hackensack New Jersey
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Mayo Clinic - Florida Jacksonville Florida
United States Northwell Health Lake Success New York
United States Froedtert and The Medical College of Wisconsin Milwaukee Wisconsin
United States Yale Cancer Center New Haven Connecticut
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Nebraska Methodist Hospital Omaha Nebraska
United States University of Kansas Cancer Center Overland Park Kansas
United States Abramson Cancer Center at Pennsylvania Hospital Philadelphia Pennsylvania
United States Mayo Clinic-Arizona Phoenix Arizona
United States Mayo Clinic, Rochester Rochester Minnesota
United States Huntsman Cancer Institute Salt Lake City Utah
United States Utah Cancer Specialists Cancer Center Salt Lake City Utah
United States Sarcoma Oncology Center Santa Monica California
United States University of California Los Angeles Santa Monica California
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States Medical Oncology Associates, P.S. Spokane Washington

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Canada,  Japan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of Treatment-emergent adverse events (TEAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 during the entire treatment period up to 23 months
Primary Occurrence of TEAEs with Grade =3 according to CTCAE version 5 during the entire treatment period up to 23 months
Secondary Occurrence of treatment-emergent serious adverse events (SAEs) up to 23 months
Secondary Occurrence of TEAEs leading to study treatment discontinuation up to 23 months
Secondary Occurrence of TEAEs leading to dose reduction up to 23 months
Secondary Occurrence of TEAEs leading to dose delay up to 23 months
Secondary Occurrence of TEAEs of special interest (adverse events of special interest [AESIs]) up to 23 months
Secondary Objective response (OR) OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (based on investigator assessment) from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anticancer therapy, lost to follow-up, or withdrawal of consent up to 23 months
Secondary Progression-free survival (PFS) PFS is defined as the time from treatment start until the earliest date of tumour progression according to RECIST version 1.1, based on investigator assessment, or death from any cause up to 23 months
Secondary Overall survival (OS) OS is defined as the time from treatment start until death from any cause up to 23 months
Secondary Duration of objective response (DOR) DOR is defined as the time from first documented confirmed OR until the earliest date of disease progression or death among patients with confirmed OR (based on investigator assessment) up to 23 months
Secondary Disease control (DC) DC is defined as a best overall response of CR, PR, or stable disease (SD) where best overall response is defined according to RECIST version 1.1 based on investigator assessment up to 23 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05218499 - Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Phase 2/Phase 3
Active, not recruiting NCT03989596 - Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Phase 2
Recruiting NCT04794127 - Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. Phase 2
Recruiting NCT05580588 - Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas Phase 2

External Links